Gabriel de Deus Vieira , Vinícius de Oliveira Boldrini , Luana Schlindwen , Ed Cleso Pereira de Souza Filho , Maria Eduarda Schulz , Felipe Fanine de Souza , Julia Petry Trevisani , Pedro Higor Campezato , Amanda Haag , Marcus Vinicius Magno Gonçalves
{"title":"Cranial neuropathies related to immune checkpoint inhibitors","authors":"Gabriel de Deus Vieira , Vinícius de Oliveira Boldrini , Luana Schlindwen , Ed Cleso Pereira de Souza Filho , Maria Eduarda Schulz , Felipe Fanine de Souza , Julia Petry Trevisani , Pedro Higor Campezato , Amanda Haag , Marcus Vinicius Magno Gonçalves","doi":"10.1016/j.jneuroim.2025.578752","DOIUrl":null,"url":null,"abstract":"<div><div>Over the last decade, monoclonal antibodies (mAbs) that function as immune checkpoint inhibitors (ICIs) have been used to treat various types of cancer. ICIs are often more effective than certain types of chemotherapy by reversing the exhaustion of CD8<sup>+</sup> T lymphocytes and NK cells induced by tumor cells to evade the antitumor immune response, acting as a targeted therapy against various cancers, unlike previous chemotherapies. However, under this treatment, patients may experience immune-related adverse events affecting multiple organs and systems, including the nervous system. Thus, we reviewed the cranial nerve involvement as a manifestation of nervous system lesions in patients receiving ICIs for cancer treatment.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"409 ","pages":"Article 578752"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825002334","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Over the last decade, monoclonal antibodies (mAbs) that function as immune checkpoint inhibitors (ICIs) have been used to treat various types of cancer. ICIs are often more effective than certain types of chemotherapy by reversing the exhaustion of CD8+ T lymphocytes and NK cells induced by tumor cells to evade the antitumor immune response, acting as a targeted therapy against various cancers, unlike previous chemotherapies. However, under this treatment, patients may experience immune-related adverse events affecting multiple organs and systems, including the nervous system. Thus, we reviewed the cranial nerve involvement as a manifestation of nervous system lesions in patients receiving ICIs for cancer treatment.
期刊介绍:
The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.